scholarly journals Carbon Nanofibers in Pure Form and in Calcium Alginate Composites Films: New Cost-Effective Antibacterial Biomaterials against the Life-Threatening Multidrug-Resistant Staphylococcus epidermidis

Polymers ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 453 ◽  
Author(s):  
Beatriz Salesa ◽  
Miguel Martí ◽  
Belén Frígols ◽  
Ángel Serrano-Aroca
Keyword(s):  
Carbon Nanofibers ◽  
Staphylococcus Epidermidis ◽  
Calcium Alginate ◽  
Composite Films ◽  
Cost Effective ◽  
Multidrug Resistant ◽  
Pure Form ◽  
Production Costs ◽  
World Health ◽  
Human Beings

Due to the current global health problem of antibiotic resistant recently announced by the World Health Organization, there is an urgent necessity of looking for new alternative antibacterial materials able to treat and impede multidrug-resistant infections which are cost-effective and non-toxic for human beings. In this regard, carbon nanofibers (CNFs) possess currently much lower cost than other carbon nanomaterials, such as graphene oxide, and exhibit excellent chemical, mechanical and electric properties. Furthermore, here, the first report on the antibacterial activity of CNFs was demonstrated. Thus, these nanomaterials, in pure form or incorporated in a minuscule amount into calcium alginate composite films to reduce production costs as much as possible, showed to be new weapons against a globally spreading multidrug-resistant pathogen, the methicillin-resistant Staphylococcus epidermidis (MRSE). This Gram-positive bacterium is becoming one of the most dangerous pathogens, due to its abundance on skin. In this study, these hollow filamentous materials, in direct contact with cells and loaded in the low-cost calcium alginate composite films, showed no cytotoxicity for human keratinocyte HaCaT cells, which render them very promising for biomedical applications. The CNFs used in this work were characterized by Raman spectroscopy and observed by high-resolution transmission electron with energy-disperse X-ray spectroscopy.

PP400 Cost-Effectiveness Analysis Of Adding Bedaquiline To Drug Regimens For Multidrug-Resistant Tuberculosis Treatment In China

2020 ◽  
Vol 36 (S1) ◽  
pp. 33-34
Author(s):  
Fan Zhang ◽  
Yuehua Liu ◽  
Zhao Liu ◽  
Zining Guo ◽  
Junting Yang ◽  
...  
Keyword(s):  
Sensitivity Analysis ◽  
Cost Effectiveness ◽  
Cost Effective ◽  
Multidrug Resistant ◽  
World Health ◽  
Tb Treatment ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Life Years ◽  
Mdr Tb

IntroductionAccording to the World Health Organization, there were approximately 0.5 million new cases of rifampicin-resistant tuberculosis in 2018, of which 78 percent were multidrug-resistant tuberculosis (MDR-TB), and China has one of the largest shares of the global burden (14%). In recent years, the Chinese government has made progress in TB control and prevention, but for MDR-TB, treatment options are still limited and expensive, and novel drugs are not always available. This research aims to evaluate the cost-effectiveness of adding bedaquiline to a background regimen (BR) of drugs for MDR-TB treatment in China, and to provide evidence for government to improve public health policies.MethodsA cohort-based Markov model was developed to evaluate the incremental cost-effectiveness ratio (ICER) of bedaquiline plus BR (BBR) versus BR alone in MDR-TB treatment, over a 10-year time horizon. Data were sourced from a phase II clinical trial, real-world data in China, published literature, and expert opinion. Outcomes were evaluated in quality-adjusted life years (QALYs) and life-years gained (LYG). The discount rate was 3.5%. Probabilistic and deterministic sensitivity analyses were conducted.ResultsThe discounted costs per person for BBR was CNY 135,706 [USD 19,172], compared with CNY 92,465 [USD 13,063] for BR. The discounted utility per person for BBR was also higher than that for BR (3.943 QALYs versus 3.193 QALYs). The ICER of BBR was CNY 58,096 [USD 8,208]/QALY, which was lower than the willingness-to-pay threshold of CNY 212,676 [USD 30,046] (three-times the gross domestic product per capita). Therefore, BBR was considered to be cost-effective. The sensitivity analysis confirmed the robustness of the results. BBR remained cost-effective in the sensitivity analysis, with a 77.2 percent probability of being cost-effective versus BR.ConclusionsIn China, bedaquiline is not included in the National Reimbursement Medicine List, which results in a heavy financial burden for MDR-TB patients. From this study, BBR was cost-effective by significantly reducing time to sputum culture conversion and increasing QALYs and LYGs, which offset the higher drug costs.

scholarly journals First report of antiviral activity of carbon nanofibers: Enhancement of the viral inhibition capacity of calcium alginate films

2020 ◽  
Author(s):  
Isaías Sanmartín-Santos ◽  
Sofía Gandía-Llop ◽  
Ángel Serrano-Aroca
Keyword(s):  
Antiviral Activity ◽  
Carbon Nanofibers ◽  
Calcium Alginate ◽  
Carbon Nanomaterials ◽  
Viral Infections ◽  
World Health ◽  
Viral Inhibition ◽  
Enveloped Virus ◽  
Double Stranded Dna ◽  
Health Organization

AbstractThe World Health Organization has called for new effective and affordable alternative antiviral materials for the prevention and treatment of viral infections. In this regard, calcium alginate has previously shown to possesses antiviral activity against the enveloped double-stranded DNA herpes simplex virus type 1. However, non-enveloped viruses are more resistant to inactivation than enveloped ones. Thus, the viral inhibition capacity of calcium alginate and the effect of adding a minuscule amount of carbon nanomaterials (0.1% w/w) have been explored here against a non-enveloped double-stranded DNA virus model for the first time. The results of this study showed that neat calcium alginate films are able to inactivate this type of non-enveloped virus and that including that extremely low percentage of carbon nanofibers significantly enhanced its viral inhibition from ~55.6% to 96.33%. This is the first published study to demonstrate CNFs’ antiviral activity. However, adding this small percentage of graphene oxide did not improve the antiviral activity of calcium alginate, although both composite biomaterials possess antiviral and other outstanding properties very promising for biomedical applications.

scholarly journals Enhancement of Antimicrobial Activity of Alginate Films with a Low Amount of Carbon Nanofibers (0.1% w/w)

2021 ◽  
Vol 11 (5) ◽  
pp. 2311
Author(s):  
Isaías Sanmartín-Santos ◽  
Sofía Gandía-Llop ◽  
Beatriz Salesa ◽  
Miguel Martí ◽  
Finn Lillelund Aachmann ◽  
...  
Keyword(s):  
Antiviral Activity ◽  
Carbon Nanofibers ◽  
Calcium Alginate ◽  
Antibacterial Properties ◽  
World Health ◽  
Viral Inhibition ◽  
Enveloped Virus ◽  
Double Stranded Dna ◽  
Antimicrobial Materials ◽  
Health Organization

The World Health Organization has called for new effective and affordable alternative antimicrobial materials for the prevention and treatment of microbial infections. In this regard, calcium alginate has previously been shown to possess antiviral activity against the enveloped double-stranded DNA herpes simplex virus type 1. However, non-enveloped viruses are more resistant to inactivation than enveloped ones. Thus, the viral inhibition capacity of calcium alginate and the effect of adding a low amount of carbon nanofibers (0.1% w/w) were explored here against a non-enveloped double-stranded DNA virus model for the first time. The results of this study showed that neat calcium alginate films partly inactivated this type of non-enveloped virus and that including that extremely low percentage of carbon nanofibers (CNFs) significantly enhanced its antiviral activity. These calcium alginate/CNFs composite materials also showed antibacterial properties against the Gram-positive Staphylococcus aureus bacterial model and no cytotoxic effects in human keratinocyte HaCaT cells. Since alginate-based materials have also shown antiviral activity against four types of enveloped positive-sense single-stranded RNA viruses similar to SARS-CoV-2 in previous studies, these novel calcium alginate/carbon nanofibers composites are promising as broad-spectrum antimicrobial biomaterials for the current COVID-19 pandemic.

Dietary and living regimen of covid-19 with special reference to Ayurveda Varsha and Sharad Ritucharya

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 758-762
Author(s):  
Amit Biswas ◽  
KunalChandankhede
Keyword(s):  
Environmental Changes ◽  
World Health ◽  
Human Beings ◽  
Dietary Regimen ◽  
Global Pandemic ◽  
The World ◽  
Health Organization ◽  
Disease Free ◽  
Individual Disease ◽  
Morbid Conditions

Wuhan originated Covid-19 disease is caused by SARC-COV 2 virus. It is a contagious disease it spread all over the world. World health organization declared a global pandemic disease. In Covid-19 immunity plays an important role. In old age people or having other co-morbid conditions the mortality rate is more. Ayurveda has a big role in improved immunity or to intact immunity. The principle of Ayurveda is to keep individual swastha (diseases free). To maintain individual disease-free Ritucharya is one of the important subjects of Ayurveda. Aimed of study is to find out Ritucharya literature from the Ayurveda and modern research specifically Varsha and Sharad ritu. Ritucharya contains dietary regimen, living modification, common medicine, and contraindicated things those changing according to environmental change. Upcoming season in India is Varsha and Sharad ritu. Environmental changes are huge in this season and it directly affected human beings. So this study reveals property of ritu, dietary regimen, living modification, common medicine and contraindicated things in upcoming varsha and sharad ritu.

An Efficient Approach for Detection and Verification of Infected Cases of Covid-19 Virus through Block Chain: A Survey

2020 ◽  
Vol 10 ◽  
Author(s):  
Kanika Gupta ◽  
Aatif Jamshed
Keyword(s):  
Data Storage ◽  
Operations Management ◽  
World Health ◽  
Chain Model ◽  
Human Beings ◽  
Healthcare Applications ◽  
Food Market ◽  
Block Chain ◽  
Novel Coronavirus ◽  
Health Organization

: Some unknown cases of pneumonia were communicated to World Health Organization (WHO) on 31 December,2019 in China’s Wuhan state. The higher authorities of China informed novel coronavirus as the root cause and labelled as “nCov-2019”. This virus is lying into the virus’s family which propagates the diseases like cold flu, lungs infection and more serious diseases. It is not detected earlier in human beings as it is considered to be a new patch on life. Many countries have increased their surveillance forces around the globe to detect any new novel coronavirus cases. An efficient and safe network for secure data storage i.e. Block chain is used in several applications such as food market, healthcare applications, finance, operations management, Internet of Things (IoT). In this paper, with the use of this emerging technology, are able to track useful information and accelerate the treatment process of patients. It also preserves the person’s identity. Correct implementation of block chain model has the chances to restrict the coronavirus transmissions and its related mortality rate where there are inadequate facilities of testing. Other infectious diseases will also be curbed by this model. The advantages of this model can reach to various stakeholders who are involved in the healthcare field which helps us to restrict the transmission of various diseases.

scholarly journals The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China

BMC Medicine ◽  
2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Chathika K Weerasuriya ◽  
Rebecca C Harris ◽  
C Finn McQuaid ◽  
Fiammetta Bozzani ◽  
Yunzhou Ruan ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Cost Effective ◽  
Multidrug Resistant ◽  
Second Line ◽  
Second Line Therapy ◽  
China And India ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Line Therapy ◽  
Mdr Tb

Abstract Background Despite recent advances through the development pipeline, how novel tuberculosis (TB) vaccines might affect rifampicin-resistant and multidrug-resistant tuberculosis (RR/MDR-TB) is unknown. We investigated the epidemiologic impact, cost-effectiveness, and budget impact of hypothetical novel prophylactic prevention of disease TB vaccines on RR/MDR-TB in China and India. Methods We constructed a deterministic, compartmental, age-, drug-resistance- and treatment history-stratified dynamic transmission model of tuberculosis. We introduced novel vaccines from 2027, with post- (PSI) or both pre- and post-infection (P&PI) efficacy, conferring 10 years of protection, with 50% efficacy. We measured vaccine cost-effectiveness over 2027–2050 as USD/DALY averted-against 1-times GDP/capita, and two healthcare opportunity cost-based (HCOC), thresholds. We carried out scenario analyses. Results By 2050, the P&PI vaccine reduced RR/MDR-TB incidence rate by 71% (UI: 69–72) and 72% (UI: 70–74), and the PSI vaccine by 31% (UI: 30–32) and 44% (UI: 42–47) in China and India, respectively. In India, we found both USD 10 P&PI and PSI vaccines cost-effective at the 1-times GDP and upper HCOC thresholds and P&PI vaccines cost-effective at the lower HCOC threshold. In China, both vaccines were cost-effective at the 1-times GDP threshold. P&PI vaccine remained cost-effective at the lower HCOC threshold with 49% probability and PSI vaccines at the upper HCOC threshold with 21% probability. The P&PI vaccine was predicted to avert 0.9 million (UI: 0.8–1.1) and 1.1 million (UI: 0.9–1.4) second-line therapy regimens in China and India between 2027 and 2050, respectively. Conclusions Novel TB vaccination is likely to substantially reduce the future burden of RR/MDR-TB, while averting the need for second-line therapy. Vaccination may be cost-effective depending on vaccine characteristics and setting.

scholarly journals Gold Nanoparticles: Can They Be the Next Magic Bullet for Multidrug-Resistant Bacteria?

Nanomaterials ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 312
Author(s):  
Mohammad Okkeh ◽  
Nora Bloise ◽  
Elisa Restivo ◽  
Lorenzo De Vita ◽  
Piersandro Pallavicini ◽  
...  
Keyword(s):  
Gold Nanoparticles ◽  
Bacterial Resistance ◽  
Multidrug Resistant ◽  
World Health ◽  
Resistant Bacteria ◽  
Magic Bullet ◽  
Global Challenge ◽  
Gold Silver ◽  
Inorganic Nanomaterials ◽  
Health Organization

In 2017 the World Health Organization (WHO) announced a list of the 12 multidrug-resistant (MDR) families of bacteria that pose the greatest threat to human health, and recommended that new measures should be taken to promote the development of new therapies against these superbugs. Few antibiotics have been developed in the last two decades. Part of this slow progression can be attributed to the surge in the resistance acquired by bacteria, which is holding back pharma companies from taking the risk to invest in new antibiotic entities. With limited antibiotic options and an escalating bacterial resistance there is an urgent need to explore alternative ways of meeting this global challenge. The field of medical nanotechnology has emerged as an innovative and a powerful tool for treating some of the most complicated health conditions. Different inorganic nanomaterials including gold, silver, and others have showed potential antibacterial efficacies. Interestingly, gold nanoparticles (AuNPs) have gained specific attention, due to their biocompatibility, ease of surface functionalization, and their optical properties. In this review, we will focus on the latest research, done in the field of antibacterial gold nanoparticles; by discussing the mechanisms of action, antibacterial efficacies, and future implementations of these innovative antibacterial systems.

PP581 Catastrophic Costs Of Multidrug-Resistant Tuberculosis: Estimation Based On The Cost Of Treatment In China

2020 ◽  
Vol 36 (S1) ◽  
pp. 43-43
Author(s):  
Lijun Shen ◽  
Shangshang Gu ◽  
Fan Zhang ◽  
Zhao Liu ◽  
Yuehua Liu
Keyword(s):  
Market Price ◽  
Multidrug Resistant ◽  
Policy Support ◽  
World Health ◽  
Chinese Patients ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Mdr Tb ◽  
Drug Affordability ◽  
The Cost

IntroductionChina bears a considerably high burden of multidrug-resistant tuberculosis (MDR-TB). Second-line anti-TB drugs are urgently needed yet domestic MDR-TB drugs are expensive and lack policy support. Patients’ living conditions are closely related to the drug affordability. The national TB prevention programs should play a critical role. The purpose of this study is to measure the cost of treating MDR-TB patients under different treatment schemes and price sources. The results of this study are expected to inform the relevant drug protection policies and provide inputs for further cost-effectiveness analyses.MethodsBased on the treatment plan of China's Multidrug-Resistant Pulmonary Tuberculosis Clinical Path (2012 edition) and the World Health Organization (WHO) Drug-Resistant Tuberculosis Treatment Guide (2018 edition), the treatment costs of MDR-TB were measured under different scenarios. Catastrophic health expenditure was then calculated if the treatment cost exceeds 40 percent of the household's non-subsistence income. National, rural and disposable income per capita in 2018, were used to represent Chinese patients’ affordability.ResultsUnder varied treatment schemes and market price sources in China, the total costs for MDR-TB patients range from 19,401 to 126,703 CNY [2,853 to 18,633 USD] per person. Under current prices, all treatment schemes recommended by the WHO will incur catastrophic costs for Chinese MDR-TB patients. Significant differences were found between rural and urban areas as 52.8 percent of the treatment listed in the 2012 China Guideline would lead to catastrophic cost for rural patients but not urban ones.ConclusionsOur study concludes that the domestic drugs are more expensive than the international purchase price and the treatment of MDR-TB imposes substantial economic burden on patients, especially in the rural areas. The results of the study also indicate that it is urgent for the state to emphasize government responsibility and initiate centralized procurement for price negotiations to reduce the market price of MDR-TB drugs. The urban-rural gap should also be addressed in the design of future policies to ensure the drug affordability for all patients in need.

scholarly journals Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety

2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Jing-Tao Gao ◽  
Juan Du ◽  
Gui-Hui Wu ◽  
Yi Pei ◽  
Meng-Qiu Gao ◽  
...  
Keyword(s):  
Adverse Events ◽  
Multidrug Resistant ◽  
World Health ◽  
Chinese Patients ◽  
Prolonged Treatment ◽  
Drug Resistant ◽  
Aminosalicylic Acid ◽  
Clinical Patient ◽  
New Drug ◽  
Resistant Tuberculosis

Abstract Background World Health Organization recommends countries introducing new drug and short treatment regimen for drug resistant tuberculosis (DR-TB) should develop and implement a system for active pharmacovigilance that allows for detection, reporting and management of adverse events. The aim of the study is to evaluate the frequency and severity of adverse events (AEs) of bedaquiline-containing regimen in a cohort of Chinese patients with multidrug-resistant (MDR)/extensively drug-resistant (XDR)-TB based on active drug safety monitoring (aDSM) system of New Drug Introduction and Protection Program (NDIP). Methods AEs were prospectively collected with demographic, bacteriological, radiological and clinical data from 54 sites throughout China at patient enrollment and during treatment between February, 2018 and December, 2019. This is an interim analysis including patients who are still on treatment and those that have completed treatment. A descriptive analysis was performed on the patients evaluated in the cohort. Results By December 31, 2019, a total of 1162 patients received bedaquiline-containing anti-TB treatment. Overall, 1563 AEs were reported, 66.9% were classified as minor (Grade 1–2) and 33.1% as serious (Grade 3–5). The median duration of bedaquiline treatment was 167.0 [interquartile range (IQR): 75–169] days. 86 (7.4%) patients received 36-week prolonged treatment with bedaquiline. The incidence of AEs and serious AEs was 47.1% and 7.8%, respectively. The most frequently reported AEs were QT prolongation (24.7%) and hepatotoxicity (16.4%). There were 14 (1.2%) AEs leading to death. Out of patients with available corrected QT interval by Fridericia's formula (QTcF) data, 3.1% (32/1044) experienced a post-baseline QTcF ≥ 500 ms, and 15.7% (132/839) had at least one change of QTcF ≥ 60 ms from baseline. 49 (4.2%) patients had QT prolonged AEs leading to bedaquiline withdrawal. One hundred and ninety patients reported 361 AEs with hepatotoxicity ranking the second with high occurrence. Thirty-four patients reported 43 AEs of hepatic injury referred to bedaquiline, much lower than that referred to protionamide, pyrazinamide and para-aminosalicylic acid individually. Conclusions Bedaquiline was generally well-tolerated with few safety concerns in this clinical patient population without any new safety signal identified. The mortality rate was generally low. These data inform significant positive effect to support the WHO recent recommendations for the wide use of bedaquiline.

Sign in / Sign up

Export Citation Format

Share Document